The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease (PR-ILD)
This study has been completed.
Sponsor:
University of California, San Francisco
Information provided by (Responsible Party):
University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT01055730
First received: January 25, 2010
Last updated: November 19, 2013
Last verified: November 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine if pulmonary rehabilitation has any effect on breathlessness, quality of life, physical function and depression in persons with interstitial lung disease.
| Condition | Intervention |
|---|---|
|
Interstitial Lung Disease |
Other: Pulmonary rehabilitation |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease: A Prospective Cohort Study |
Resource links provided by NLM:
Genetics Home Reference related topics:
pulmonary alveolar microlithiasis
MedlinePlus related topics:
Breathing Problems
Interstitial Lung Diseases
Lung Diseases
Rehabilitation
U.S. FDA Resources
Further study details as provided by University of California, San Francisco:
Primary Outcome Measures:
- 6-minute walk distance [ Time Frame: Immediately following completion of pulmonary rehabilitation and 6 months following the start of pulmonary rehabilitation ] [ Designated as safety issue: No ]
- Quality of life [ Time Frame: Immediately following completion of pulmonary rehabilitation and 6 months following the start of pulmonary rehabilitation ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Dyspnea [ Time Frame: Immediately following completion of pulmonary rehabilitation and 6 months following the start of pulmonary rehabilitation ] [ Designated as safety issue: No ]
- Depression [ Time Frame: Immediately following completion of pulmonary rehabilitation and 6 months following the start of pulmonary rehabilitation ] [ Designated as safety issue: No ]
| Enrollment: | 54 |
| Study Start Date: | February 2010 |
| Study Completion Date: | January 2013 |
| Primary Completion Date: | January 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
| Pulmonary rehabilitation |
Other: Pulmonary rehabilitation
Structured education and supervised exercise program, lasting between 6 and 9 weeks.
|
Eligibility| Ages Eligible for Study: | 19 Years and older (Adult, Senior) |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Any patient with interstitial lung disease who is referred to a participating pulmonary rehabilitation program. These patients typically have exercise limitation and dyspnea, but still possess the ability to perform some exercise.
Criteria
Inclusion Criteria:
- Adults (> 18 years old) with a diagnosis of ILD who are referred to a participating PR program
Exclusion Criteria:
- Inability to provide informed consent
- Inability to read and write English
- Any other medical condition that significantly limits the subject's ability to perform the functional measures
- Emphysema / Chronic bronchitis (FEV1 / FVC ratio < 60%)
- Previous pulmonary rehabilitation
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01055730
Please refer to this study by its ClinicalTrials.gov identifier: NCT01055730
Locations
| United States, California | |
| John Muir Health | |
| Concord, California, United States, 94520 | |
| Seton Pulmonary & Cardiac Rehabilitation | |
| Daly City, California, United States, 94015 | |
| United States, Connecticut | |
| Yale University School of Medicine | |
| New Haven, Connecticut, United States, 06520-8057 | |
| United States, North Carolina | |
| Duke University Medical Center | |
| Durham, North Carolina, United States, 27710 | |
| United States, Virginia | |
| Inova Fairfax Hospital | |
| Falls Church, Virginia, United States, 22042 | |
| Canada, British Columbia | |
| University of British Columbia | |
| Vancouver, British Columbia, Canada, V6Z 1Y6 | |
Sponsors and Collaborators
University of California, San Francisco
Investigators
| Principal Investigator: | Harold R Collard, MD | University of California, San Francisco |
| Principal Investigator: | Christopher J Ryerson, MD | University of California, San Francisco |
| Principal Investigator: | Chris Garvey, FNP | Seton Pulmonary & Cardiac Rehabilitation |
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | University of California, San Francisco |
| ClinicalTrials.gov Identifier: | NCT01055730 History of Changes |
| Other Study ID Numbers: | PR-ILD |
| Study First Received: | January 25, 2010 |
| Last Updated: | November 19, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of California, San Francisco:
|
Pulmonary rehabilitation Exercise therapy Interstitial lung disease Pulmonary fibrosis |
Mobility limitation Dyspnea Mental health |
Additional relevant MeSH terms:
|
Lung Diseases Lung Diseases, Interstitial Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on September 28, 2016